Topical Medical Therapies for Ocular Surface Tumors

We review the use of three topical medications for the therapy of ocular surface tumors: mitomycin C, 5-fluorouracil, and interferon alpha-2B. One hundred sixty patients with histologically or cytologically proven epithelial and melanocytic tumors were identified in the literature. Side effects occu...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in ophthalmology 2006-01, Vol.21 (3), p.161-169
Main Authors: Poothullil, Antony M., Colby, Kathryn A.
Format: Article
Language:English
Subjects:
Administration, Topical
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Carcinoma in Situ - drug therapy
Carcinoma in Situ - pathology
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - pathology
conjunctival lymphoma
Conjunctival Neoplasms - drug therapy
Conjunctival Neoplasms - pathology
conjunctival squamous cell carcinoma
conjunctival tumors
Corneal Diseases - drug therapy
Corneal Diseases - pathology
Eye Neoplasms - drug therapy
Eye Neoplasms - pathology
Fluorouracil - administration & dosage
Fluorouracil - adverse effects
Humans
interferon alpha-2B
Interferon-alpha - administration & dosage
Interferon-alpha - adverse effects
Lymphoma - drug therapy
Lymphoma - pathology
Mitomycin - administration & dosage
Mitomycin - adverse effects
mitomycin C
ocular surface tumors
Recombinant Proteins
Sebaceous Gland Neoplasms - drug therapy
Sebaceous Gland Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We review the use of three topical medications for the therapy of ocular surface tumors: mitomycin C, 5-fluorouracil, and interferon alpha-2B. One hundred sixty patients with histologically or cytologically proven epithelial and melanocytic tumors were identified in the literature. Side effects occurred most often with mitomycin C, followed by 5-fluorouracil, and interferon alpha-2B. Patients most frequently experienced transient keratitis, redness, and irritation. Topical agents were used as both primary and adjuvant therapy. Rates of tumor regression for CIN and squamous cell carcinoma ranged from 80 to 96%, and 70% of pigmented tumors regressed after an average follow-up of 27 months.
ISSN:0882-0538
1744-5205
DOI:10.1080/08820530500351694